EAM
ADAP

Erste Asset Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Erste Asset Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-90,000
Closed -$154K – 556
2022
Q2 		$154K Hold
90,000
– – ﹤0.01% 530
2022
Q1 		$185K Hold
90,000
– – ﹤0.01% 510
2021
Q4 		$333K Hold
90,000
– – 0.01% 466
2021
Q3 		$468K Buy
+90,000
New +$404K 0.01% 425

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Erste Asset Management's ADAP Position: Q3 2022 in Review

Erste Asset Management sold out of Adaptimmune Therapeutics (ADAP) in Q3 2022, closing a stake of 90,000 shares — an estimated $154K sold.

Erste Asset Management first reported a position in ADAP in Q3 2021 and held it in 4 quarters. The position peaked at $468K in Q3 2021. 68 funds tracked by Wall St. Rank hold ADAP as of Q3 2022.

  • Erste Asset Management reported no remaining Adaptimmune Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Erste Asset Management sold 90,000 Adaptimmune Therapeutics shares in Q3 2022, an estimated $154K.
  • Erste Asset Management first reported a position in Adaptimmune Therapeutics in Q3 2021 and held it in 4 quarters.
  • Erste Asset Management's Adaptimmune Therapeutics position peaked at $468K in Q3 2021.
  • 68 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2022.

Based on Erste Asset Management's 13F filing for Q3 2022, filed 26 Nov 2024.